Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Accelerating Drug Discovery: AI-Powered Indication Exploration for Ropeginterferon Alfa-2b

Erik R Sampson, Yi-Chien Chang, Kuan-Chun Huang, Tom Lin, Prasanna Baskar, Mei-Ling Yang, Ali Sepahi, Dobeen Hwang, Jack Huck, Ming-Tang Chen, Emily Huang, Ivana Grbesa, Francesco Lamanna, Andreas Kramer, Andrew Srisuwananukorn, Lih-Ling Lin

Blood (2024) 144 (Supplement 1): 4982.

https://doi.org/10.1182/blood-2024-210640

Published: 2024

Journal Articles

Second Primary Hematological Malignancy in Multiple Myeloma Patients Exposed to Lenalidomide and Autologous Stem Cell Transplantation

Justin Jiang, Joshua Galloway, Andrew Srisuwananukorn, Uma Borate, Nidhi Sharma, Naresh Bumma, Srinivas Devarakonda, Elvira Umyarova, Ashley Rosko, Abdullah Mohammad Khan, Don Benson, Francesca Cottini

Blood (2024) 144 (Supplement 1): 6954.

https://doi.org/10.1182/blood-2024-198754

Published: 2024

Journal Articles

Real World Outcomes of Patients (Pts) with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) or Therapy-Related AML (t-AML) Receiving Venetoclax-Based Therapies

Kelly Pugh, Michael C Walker, Deedra Nicolet, Victoria Klein, Krzysztof Mrózek, Gregory K Behbehani, James S. Blachly, Uma Borate, Nicole R. Grieselhuber, Kristin L Koenig, Karilyn T. Larkin, Meixiao Long, Andrew Srisuwananukorn, Ann-Kathrin Eisfeld, Alice Mims

Blood (2024) 144 (Supplement 1): 7929.

https://doi.org/10.1182/blood-2024-210135

Published: 2024

Journal Articles

Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2432.

https://doi.org/10.1182/blood-2024-203704

Published: 2024

Journal Articles

Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

Blood (2024) 144 (Supplement 1): 7303.

https://doi.org/10.1182/blood-2024-194146

Published: 2024

Journal Articles

GATA2 -Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 7309.

https://doi.org/10.1182/blood-2024-202650

Published: 2024

Journal Articles

A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Uma Borate, Kaitlyn M. Dvorak-Kornaus, Qiuhong Zhao, Roland B. Walter, Rachel J. Cook, Jennifer N. Saultz, Ronan T. Swords, Nicole R. Grieselhuber, Alice Mims, Karilyn T. Larkin, Kieran D Sahasrabudhe, James S. Blachly, Gregory K Behbehani, Ann-Kathrin Eisfeld, Meixiao Long, Andrew Srisuwananukorn, Kristin L Koenig

Blood (2024) 144 (Supplement 1): 4286.

https://doi.org/10.1182/blood-2024-210605

Published: 2024

Journal Articles

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis

Douglas Tremblay, Zaker I. Schwabkey, Yosef Joseph Rene Amel Riazat-Kesh, Grace Van Hyfte, Najla H Al Ali, Julian Waksal, Andrew Srisuwananukorn, Rami S. Komrokji, John Mascarenhas, Andrew T. Kuykendall

Blood (2023) 142 (Supplement 1): 1830.

https://doi.org/10.1182/blood-2023-179937

Published: 2023

Journal Articles

Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool

Andrew Srisuwananukorn, Giuseppe Gaetano Loscocco, Andrew T. Kuykendall, James M Dolezal, Raffaella Santi, Ling Zhang, Avani M Singh, Paola Guglielmelli, Alessandro Maria Vannucchi, Douglas Tremblay, Alexander T Pearson, Mohamed E. Salama, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 901.

https://doi.org/10.1182/blood-2023-173877

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine Is a Tolerable and Effective Ambulatory Regimen for Patients with Advanced Myeloproliferative Neoplasms

Ganesh Sivakumar, Shivani Handa, Andrew Srisuwananukorn, Douglas Tremblay, John Mascarenhas, Marina Kremyanskaya, Yelena Ginzburg, Xiaoli Wang, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 1828.

https://doi.org/10.1182/blood-2023-178822

Published: 2023

Journal Articles

Predictors and Clinical Complications Associated with Antiphospholipid Antibodies in Sickle Cell Disease

Claudia Rodriguez Rivera, Andrew Srisuwananukorn, Rizma Jalees Bajwa, Victor R. Gordeuk, Joyce Rauch, Jerrold Levine, Santosh L. Saraf

Blood (2022) 140 (Supplement 1): 8278–8279.

https://doi.org/10.1182/blood-2022-163851

Published: 2022

Journal Articles

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

Blood (2021) 138 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2021-150561

Published: 2021

Journal Articles

A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients

Ghaith Abu-Zeinah, Spencer Krichevsky, Richard T. Silver, Elwood Taylor, III, Douglas Tremblay, Andrew Srisuwananukorn, John Mascarenhas, Joseph Scandura

Blood (2021) 138 (Supplement 1): 3619.

https://doi.org/10.1182/blood-2021-149098

Published: 2021

Journal Articles

Defining and Predicting Rapid Egfr Decline in Sickle Cell Disease

Santosh L. Saraf, Jin Han, Maria Armila Ruiz, Andrew Srisuwananukorn, David Shuey, Faiz Ahmed Hussain, Franklin Njoku, Robert E. Molokie, Victor R. Gordeuk

Blood (2021) 138 (Supplement 1): 122.

https://doi.org/10.1182/blood-2021-147861

Published: 2021

Journal Articles

European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database

Douglas Tremblay, Andrew Srisuwananukorn, Lukas Ronner, Nikolai Podoltsev, Jason Gotlib, Mark L. Heaney, Andrew T. Kuykendall, Casey L. O'Connell, Jamile M. Shammo, Angela Fleischman, Ruben A. Mesa, Abdulraheem Yacoub, Ronald Hoffman, Erin Moshier, Nicole Zubizarreta, John Mascarenhas

Blood (2021) 138 (Supplement 1): 240.

https://doi.org/10.1182/blood-2021-148020

Published: 2021

Journal Articles

Lower Apache II Score and Exchange Transfusions Predict Better Outcomes in the Intensive Care Unit for Patients with Sickle Cell Disease

Renee Cheng, MD, Andrew Srisuwananukorn, MD, Jin Han, Michel Gowhari, DO, Franklin Njoku, MD, Faiz Ahmed Hussain, MD, Robert E. Molokie, MD, Victor R. Gordeuk, MD, Santosh L. Saraf, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-137272

Published: 2020

Journal Articles

Correction of Point-of-Care International Normalized Ratio (INR) Values in Patients with Sickle Cell Disease

Syeda Rahman, Andrew Srisuwananukorn, MD, Robert E. Molokie, MD, Michel Gowhari, DO, Franklin Njoku, MD, Faiz Ahmed Hussain, MD, Edith A. Nutescu, PharmD., MS, FCCP, Victor R. Gordeuk, MD, Santosh L. Saraf, MD, Jin Han

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-137166

Published: 2020

Journal Articles

Effects of Hydroxyurea and Renin-Angiotensin Blockade on Kidney Function in Sickle Cell Disease

Jin Han, Andrew Srisuwananukorn, MD, Michel Gowhari, DO, Faiz Ahmed Hussain, MD, Franklin Njoku, MD, Robert E. Molokie, MD, Victor R. Gordeuk, MD, Santosh L. Saraf, MD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-138753

Published: 2020

Journal Articles

Cancer Incidence and Chemotherapy Tolerance in Patients with Sickle Cell Disease

Mahir Khan, MD, Andrew Srisuwananukorn, MD, Santosh L. Saraf, MD, Faiz Ahmed Hussain, MD, Robert E. Molokie, MD, Michel Gowhari, DO, Victor R. Gordeuk, MD, Franklin Njoku, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-139653

Published: 2020

Journal Articles

Type 2 Diabetes Mellitus in Patients with Sickle Cell Disease: A Population-Based Longitudinal Analysis of Three Cohorts

Jifang Zhou, MD, Jin Han, PharmD, PhD, Edith A. Nutescu, PharmD., MS, FCCP, William Galanter, MD PhD MS, Surrey M. Walton, PhD, Victor R. Gordeuk, MD, Santosh L. Saraf, MD, Andrew Srisuwananukorn, MD, Gregory Sampang Calip, PharmD, MPH, PhD

Blood (2018) 132 (Supplement 1): 4817.

https://doi.org/10.1182/blood-2018-99-119039

Published: 2018

NARROW

Accelerating Drug Discovery: AI-Powered Indication Exploration for Ropeginterferon Alfa-2b

Second Primary Hematological Malignancy in Multiple Myeloma Patients Exposed to Lenalidomide and Autologous Stem Cell Transplantation

Real World Outcomes of Patients (Pts) with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) or Therapy-Related AML (t-AML) Receiving Venetoclax-Based Therapies

Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia

Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

GATA2 -Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation

A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis

Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool

Oral Decitabine/Cedazuridine Is a Tolerable and Effective Ambulatory Regimen for Patients with Advanced Myeloproliferative Neoplasms

Predictors and Clinical Complications Associated with Antiphospholipid Antibodies in Sickle Cell Disease

Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics

A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera (PV) Patients

Defining and Predicting Rapid Egfr Decline in Sickle Cell Disease

European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database

Lower Apache II Score and Exchange Transfusions Predict Better Outcomes in the Intensive Care Unit for Patients with Sickle Cell Disease

Correction of Point-of-Care International Normalized Ratio (INR) Values in Patients with Sickle Cell Disease

Effects of Hydroxyurea and Renin-Angiotensin Blockade on Kidney Function in Sickle Cell Disease

Cancer Incidence and Chemotherapy Tolerance in Patients with Sickle Cell Disease

Type 2 Diabetes Mellitus in Patients with Sickle Cell Disease: A Population-Based Longitudinal Analysis of Three Cohorts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only